Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
TIAMATE (diltiazem malate) is an oral extended-release calcium channel blocker tablet approved by the FDA in 1996. It is indicated for the management of hypertension and angina pectoris by reducing cardiac workload and dilating coronary arteries. Diltiazem works by inhibiting calcium influx into vascular smooth muscle and cardiac cells, leading to vasodilation and reduced heart rate.
As LOE approaches, the brand team is likely rightsizing and shifting focus toward lifecycle management and generic partnership strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TIAMATE offers limited career growth due to its mature lifecycle stage and approaching loss of exclusivity. Roles available are primarily focused on defending market share, managing generic transition, and optimizing sales of remaining exclusivity—making this suitable for professionals seeking stability rather than high-growth opportunity.
Worked on TIAMATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo